<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01933646</url>
  </required_header>
  <id_info>
    <org_study_id>V98_23OB</org_study_id>
    <nct_id>NCT01933646</nct_id>
  </id_info>
  <brief_title>Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China</brief_title>
  <official_title>Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China: Incidence, Case Fatality Rate and Serotype Distribution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the burden of invasive group B streptococcal (GBS) disease in young infants (up to
      90 days of age) in China, in terms of incidence, case fatality rate and serotype
      distribution
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of group B streptococcal (GBS) disease</measure>
    <time_frame>From birth to 90 days of age</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Case Fatality Rate of GBS disease</measure>
    <time_frame>From birth to 90 days of age</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>GBS serotype distribution</measure>
    <time_frame>From birth to 90 days of age</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Invasive Group B Streptococcal Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Infants (up to and including 90 days of age) born in or treated in a study hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive culture for GBS from one or more of the following normally sterile sites:
             blood, cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, pericardial fluid,
             surgical aspirate, bone, joint fluid, suprapubic bladder aspiration or internal body
             site (e.g., lymph node, brain).

          2. â‰¤90 days old at the time of GBS confirmation.

          3. Voluntary written informed consent provided.

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Drug Informaton Services</last_name>
    <phone>+1 800 244 7668</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Women and Children's Medical Centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiying Liu, Dr</last_name>
      <email>xiangliuhaiying@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://ieaweb.org/2010/04/good-epidemiological-practice-gep/</url>
    <description>Good Epidemiological Practice: 2007</description>
  </link>
  <reference>
    <citation>Heath PT, Schuchat A. Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol. 2007 Jun;21(3):411-24. Epub 2007 Mar 2. Review.</citation>
    <PMID>17336588</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Group B streptococcus</keyword>
  <keyword>Incidence</keyword>
  <keyword>Case fatality rate</keyword>
  <keyword>Serotype distribution</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
